drugset
drugset / Trial / NCT03607643

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643 ↗

Phase 1/2 Unknown 160 enrolled Leaf Vertical Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI Malignancies

Timeline

Start
2019-01-15
Primary completion
2020-06-30
Completion
2020-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 1 ml Other
Background Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Background Bortezomib Small molecule 1.3 mg/m2 —
Background Gemcitabine Small molecule 1000 mg/m2 —
Background Irinotecan Small molecule — —
Background Leucovorin Small molecule 350 mg/m2 Intravenous
Background Oxaliplatin Small molecule 100 mg/m2 Intravenous
Background Temozolomide Small molecule 150 mg/m2 —
Background Temozolomide Small molecule 200 mg/m2 —
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colon carcinoma gallbladder cancer glioblastoma liver cancer malignant pancreatic neoplasm plasma cell myeloma rectal cancer